December 5, 2012

PVCT: A Reminder of Property Rights

Click figure to enlarge.
Provectus News earlier this week noted an article on Provectus' combination therapy patent application (made jointly with Pfizer).
Click figure to enlarge.
While management included the combination of PV-10 and anti-CTLA-4 antibodies like ipi (Bristol-Myers) and tremi (Pfizer/MedImmune-AstraZeneca) in Provectus' patent application, Bristol-Myers did not include PV-10 in its patent of combination therapies with Yervoy.

No comments:

Post a Comment